Allogene Therapeutics
Lin Feng, Ph.D., is a Principal Specialist in Quality Control at Allogene Therapeutics, with extensive experience in analytical method development and validation in the biopharmaceutical sector. Prior roles include Senior Specialist at Allogene Therapeutics, Scientist at Avid Bioservices and Nitto Avecia Pharma Services, and key positions at Irvine Pharmaceutical Services and the University of California. A Ph.D. in Cell/Cellular and Molecular Biology from Nanyang Technological University and an M.D. in Clinical Medicine from Southeast University support Lin Feng's deep expertise in molecular biology techniques, bioassay optimization, and project management. Additional skills encompass proficiency in various cell-based assays and strong scientific communication capabilities.
This person is not in any teams
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.